Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

J Neurooncol. 1996 Dec;30(3):243-6. doi: 10.1007/BF00177275.

Abstract

Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antidotes / therapeutic use*
  • Antidotes / toxicity
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antimetabolites, Antineoplastic / toxicity
  • Astrocytoma / drug therapy*
  • Brain Neoplasms / drug therapy*
  • Female
  • Fluorouracil / therapeutic use*
  • Fluorouracil / toxicity
  • Humans
  • Leucovorin / therapeutic use*
  • Leucovorin / toxicity
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Oligodendroglioma / drug therapy*
  • Recurrence
  • Stomatitis / chemically induced
  • Thrombocytopenia / chemically induced

Substances

  • Antidotes
  • Antimetabolites, Antineoplastic
  • Leucovorin
  • Fluorouracil